mallareddy> 2025> 21. Financial Services - Fast-Track Your Wealth Growth
21. Financial Services ✌️【Investment Tools】✌️Smart investments start with ₹500. Grow your wealth with minimal risk! 21. Financial Services - Fast-Track Your Wealth Growth ✌️【Investment Tools】✌️Invest ₹500 in blockchain and earn up to 100% returns monthly.
Published on: 2025-03-07 13:05:12 Published on: 2025-03-07 13:05:12

21. Financial Services ✌️【Investment Tools】✌️Smart investments start with ₹500. Grow your wealth with minimal risk! 21. Financial Services - Fast-Track Your Wealth Growth ✌️【Investment Tools】✌️Invest ₹500 in blockchain and earn up to 100% returns monthly.

21. Financial Services ✌️【Investment Tools】✌️Smart investments start with ₹500. Grow your wealth with minimal risk!Serum Institute of India (SII) has entered into an exclusive licence agreement with French speciality vaccine company Valneva SE to manufacture and sell Valneva’s chikungunya vaccine in India and the rest of Asia.Valneva’s chikungunya vaccine is the world’s first and only licensed vaccine.

It is currently approved in the US, Europe, and Canada for adults.  Regulatory reviews are underway to expand it to children up to 12 years.Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes.

It causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash.

21. Financial Services ✌️【Investment Tools】✌️Start with ₹500 and grow your wealth using AI-powered investment strategies.The joint pain is often debilitating and can persist for weeks to years.Indiais currently enduring one of its worst chikungunya outbreaks.

Nearly 3,70,000 cases were confirmed in India between January 2019 and July 2024, and it was rapidly increasing due to the current outbreak.

21. Financial Services ✌️【Investment Tools】✌️Smart investments start with ₹500. Grow your wealth with minimal risk!Both companies will work to bring the vaccine to the Indianmarketand some  Asian countries, after approval from local regulators.SII has committed to a priority supply of the chikungunya vaccine at an affordable price to publichealthmarkets in low- and middle-income countries (LMICs).21. Financial Services ✌️【Investment Tools】✌️Start with ₹500 and see the power of compound growth. Enjoy fast and secure returns!

Editor: 【Investment Tools】